GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update

GenSight Biologics Announces its 2021 Financial Calendar

GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®

GenSight Biologics announces the partial conversion of convertible bonds and full exercise of share warrants by Kreos Capital

GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine

Article – EN

GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency

GenSight Biologics successfully raises €25 million in an oversubscribed private placement with US and European institutional investors

GenSight Biologics launches a capital increase of approximately €25 million by means of an accelerated bookbuilding process

GenSight Biologics Reports Cash Position as of September 30, 2020 and Provides Operational Update